May 5, 2016

Expanding Our Cystic Fibrosis Collaboration with Galapagos

The cystic fibrosis (CF) combination therapy we are developing with Galapagos is on track. Following successful completion of Phase 2 development, AbbVie will be responsible for Phase 3.
Share to Facebook Share to Twitter Share to Linkedin Email Sign Up for Alerts Print
With a potential breakthrough triple combination therapy for cystic fibrosis (CF) in development, AbbVie and Galapagos are aspiring to address 90 percent of patients with cystic fibrosis. Upon successful completion by Galapagos of clinical development through to completion of Phase 2, AbbVie will be responsible for Phase 3 development.
CF is a rare, life-threatening, genetic disease that affects approximately 80,000 patients worldwide. It is a chronic disease that affects the lungs and digestive system. CF patients, with significantly impaired quality of life, have an average lifespan approximately 50 percent shorter than the population average, with the median age of death at 40. There currently is no cure for CF.
Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action.

Learn more by reading the Galapagos press release.